论文部分内容阅读
目的:评价进口普罗帕酮治疗室性早搏的疗效及安全性。方法:采用随机分组、美西律平行对照的方法,对其进行了研究;入选患者共107例,男性47例,女性60例,年龄为(45.8±12.4)a,进口普罗帕酮组71例,其中男性34例,女性37例,年龄为(45.3±13.5)a;美西律组36例,男性13例,女性23例,年龄为(46.8±10.0)a。结果:进口普罗帕酮组的有效率为54.9％;美西律组的有效率为66.2％;2组有效率经x~2检验P>0.05,无统计学意义;进口普罗帕酮组治疗前后P-R间期经t检验,延长有统计学意义P<0.05),对ECG的其他指标在治疗前后均无统计学意义(P>0.05);美西律组在治疗前后对ECG的各指标无统计学意义(P>0.05)。2组治疗前后ECG各指标的改变经t检验无统计学意义(P>0.05)。进口普罗帕酮组不良反应的发生率为14.1％,与心脏有关的不良反应6例,占不良反应的60％;美西律组有3例出现不良反应,发生率为8.3％,未观察到与心脏有关的不良反应;2组均无死亡及因心脏不良反应出现严重的事件;经x~2检验,2组不良反应发生率无统计学意义(P>0.05)。未发现肝、肾功能损害。结论:服用进口普罗帕酮600mg·d~(-1)(含600mg·d~(-1))以下治疗室性早搏,有效、安全,但由于病例较少,结果仅供参考。
Objective: To evaluate the efficacy and safety of imported propafenone in the treatment of premature ventricular contractions. Methods: A randomized study was conducted by means of randomized grouping and mexiletine parallel control. A total of 107 patients were enrolled, including 47 males and 60 females, with an average age of 45.8 ± 12.4 and a group of 71 propafenone groups There were 34 males and 37 females, with a mean age of (45.3 ± 13.5) years. There were 36 cases of mexiletine, 13 males and 23 females with an average age of 46.8 ± 10.0 years. Results: The effective rate of imported propafenone group was 54.9%; the effective rate of mexiletine group was 66.2%; the effective rate of 2 groups was no significant difference after x ~ 2 test (P> 0.05) PR interval by the t test, prolonged statistically significant P <0.05), other indicators of ECG before and after treatment were not statistically significant (P> 0.05); before and after treatment with the United States Xi Lu ECG indicators without statistics Significance (P> 0.05). Before and after treatment, ECG changes in each index by t test was not statistically significant (P> 0.05). The incidence of adverse reactions in imported propafenone group was 14.1%, heart-related adverse reactions in 6 cases, accounting for 60% of the adverse reactions; 3 cases of the American West Group adverse reactions, the incidence was 8.3%, not observed There were no deaths and serious events due to adverse cardiac reactions in the two groups. There was no significant difference in adverse reactions between the two groups (P> 0.05). No liver or kidney damage was found. Conclusion: It is effective and safe to take propafenone 600mg · d -1 (including 600mg · d -1) for the treatment of ventricular premature beats, but the results are only for reference.